via NEWMEDIAWIRE -- World High Life Plc (NEX: LIFE), a CBD and
medicinal cannabis investment vehicle, is pleased to announce that
trading in its Ordinary Shares will commence at 8.00 a.m. today on
the NEX Exchange Growth Market ("Admission"), under ticker LIFE and
ISIN number GB00BK777P75. The Company will look to identify
investment opportunities in the medicinal cannabis, hemp and CBD
sectors globally with a particular interest in the UK and European
markets.
The Company’s investment strategy will focus on markets that are
internationally recognised as having well-developed and reputable
laws and regulations relating to the research and production of
medicinal cannabis, hemp and CBD, as well as therapeutic Cannabis
derivatives including but not limited to nutraceuticals, dietary
supplements and cosmetic products. The Directors believe that
there are numerous investment opportunities within the CBD wellness
industry, the hemp industry and the medicinal cannabis
industry.
Key Highlights
· On
Admission the Company will have raised £2.4 million and will have
110,398,091 Ordinary Shares in issue.
· The
Company will undertake due diligence on investment opportunities
encompassing the breadth of the medicinal cannabis, hemp and CBD
Sectors.
· The
Board will continue to monitor the global deregulation of medicinal
cannabis with a particular focus on Europe to ensure the Company is
best placed to take advantage once deregulation occurs.
· The
Directors have over 30 years’ experience on TSX, CSE and OTC public
markets and intend to replicate proven models from their success
with North American cannabis companies.
· Funds
initially available to the Company will be used to meet general
working capital requirements, undertake due diligence on potential
target acquisitions and to make investments in accordance with the
investment guidelines described above.
· The
Global CBD market is set to increase from $270 million in 2018 to
$3.86 billion by 2025, with the global medical cannabis market
forecast to reach $148.35 billion by 2026.
Management with a Strong Track of Generating
Returns to Investors
World High Life was established by the Founders of
Supreme Cannabis and 1933 Industries. Both companies are at the
forefront of the legalised cannabis landscape in North America.
David Stadnyk – Chairman and Chief Executive
Officer (Aged 56)
David is the founder and senior partner of Stadnyk
& Partners, a venture capital investment firm focused on small
cap companies in the resources, biotech and pharmaceuticals
sectors, headquartered in Vancouver. He has over 30 years’
experience of founding and developing both public and private
companies.
David has been at the forefront of the cannabis
sector in Canada since 2012 and was a key contributor to the
Marijuana for Medical Purposes Regulations which were in place
between 2013 and 2016. He has been involved with a number of
companies in the space including The Supreme Cannabis Company, 1933
Industries, FSD Pharma and Weekend Unlimited.
David previously owned the Vancouver Whitecaps
soccer club and is a co-founder of the TSN 1040 Sports Radio
Station in Vancouver. He serves as Chair of the Stadnyk Foundation,
a not-for-profit society established to recognize and promote sport
philanthropy among athletes, coaches and executives.
Robert Payment – Chief Financial Officer (Aged
37)
Robert is a Chartered Professional Accountant with
12 years’ experience in finance, reporting, regulatory
requirements, public company administration, equity markets, and
financing of publicly traded companies. He commenced his career in
private practise and since 2014 he has served as a consultant for a
number of TSX Venture Exchange and Canadian Securities Exchange
(CSE) listed companies.
Robert has extensive experience in the cannabis,
manufacturing, natural resource, and retail industries. He received
a BBA from Simon Fraser University and is a member in good standing
of the Chartered Professional Accountants of British Columbia.
Kevin Ernst – Non-Executive Director (Aged
55)
Kevin has over 30 years’ experience in the
investment banking industry having started his career in wealth
management with Merrill Lynch and then UBS before spending nine
years at the New York Stock Exchange with responsibility for over
150 listings of North American and Asia-Pacific companies. Kevin is
currently a partner in a Toronto based private equity group that
specialises in strategic advisory and investments into private
technology and healthcare companies.
Kevin holds both an Economics degree and an MBA
from Rutgers University as well as NASD securities licences.
Charles (Charlie) Lamb – Independent Non-
Executive Director (Aged 37)
Charlie has over 10 years of experience working as
a Canadian corporate and securities lawyer at a large international
law firm in New York. With extensive cross-border corporate and
securities law experience, Charlie has worked on numerous corporate
transactions, including mergers and acquisitions, public and
private offerings of securities for investment funds, private
equity funds and other alternative investment vehicles in the
Canadian markets. He also has significant experience advising
broker dealers, advisers and investment fund managers on Canadian
compliance issues.
Charlie graduated from the University of Victoria,
British Columbia and is a member of the Law Society of Upper
Canada, The Canadian Bar Association and the American Bar
Association. He has resided in New York since 2009.
David Stadnyk, Chairman and Chief Executive
Officer commented:
“We are delighted to be trading on the NEX
Exchange today. This is an exciting time for the Company and for
the medical cannabis and CBD sector in Europe, with many
forecasting huge growth over the next few years.
“I have a strong team around me, many of whom have
years of experience and much success investing in the cannabis
market in North America. We believe that there are numerous
investment opportunities here in Europe that will generate great
returns for our shareholders, and we look forward to updating the
market with our developments.”
For further information please contact:
David Stadnyk
Founder & CEO
World High Life
+44 (0) 7926 397 675
info@worldhighlife.uk
NEX Exchange Corporate Adviser
Mark Anwyl/ Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7469 0930
ma@peterhousecap.com
af@peterhousecap.com
Financial PR
Camilla Horsfall/ Julia Tilley
Blytheweigh
+44 (0) 20 7138 3224
Camilla.horsfall@blytheweigh.com
Julia.tilley@blytheweigh.com
For more information on World High Life please
visit: www.worldhighlife.uk
Forward Looking Statements
Certain information set forth in this news release may contain
forward-looking statements that involve substantial known and
unknown risks and uncertainties. All statements other than
statements of historical fact are forward-looking statements,
including, without limitation, statements regarding future
financial position, business strategy, use of proceeds, corporate
vision, proposed acquisitions, partnerships, joint-ventures and
strategic alliances and co-operations, budgets, cost and plans and
objectives of or involving the Company. Such forward-looking
information reflects management's current beliefs and is based on
information currently available to management. Often, but not
always, forward-looking statements can be identified by the use of
words such as "plans", "expects", "is expected", "budget",
"scheduled", "estimates", "forecasts", "predicts", "intends",
"targets", "aims", "anticipates" or "believes" or variations
(including negative variations) of such words and phrases or may be
identified by statements to the effect that certain actions "may",
"could", "should", "would", "might" or "will" be taken, occur or be
achieved. A number of known and unknown risks, uncertainties and
other factors may cause the actual results or performance to
materially differ from any future results or performance expressed
or implied by the forward-looking information. These
forward-looking statements are subject to numerous risks and
uncertainties, certain of which are beyond the control of the
Company including, but not limited to, the impact of general
economic conditions, industry conditions and dependence upon
regulatory approvals. Readers are cautioned that the assumptions
used in the preparation of such information, although considered
reasonable at the time of preparation, may prove to be imprecise
and, as such, undue reliance should not be placed on
forward-looking statements. The Company does not assume any
obligation to update or revise its forward-looking statements,
whether as a result of new information, future events, or
otherwise, except as required by securities laws.
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024